Efficacy and safety of ritlecitinib (PF06651600) in patients with alopecia areata and at least 50% scalp hair loss: results from the international ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled study (NCT03732807)
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要